Home/Filings/4/0000899243-17-024262
4//SEC Filing

Zhao Hong 4

Accession 0000899243-17-024262

CIK 0000880771other

Filed

Oct 15, 8:00 PM ET

Accepted

Oct 16, 5:14 PM ET

Size

27.5 KB

Accession

0000899243-17-024262

Insider Transaction Report

Form 4
Period: 2017-10-13
Zhao Hong
CEO, China Operations
Transactions
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$2.35/sh84,000$197,4000 total
    Exercise: $8.83Exp: 2025-03-16Common Stock (84,000 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$6.66/sh90,000$599,4000 total
    Exercise: $4.52Exp: 2024-03-14Common Stock (90,000 underlying)
  • Disposition to Issuer

    Common Stock

    2017-10-13$11.18/sh127,000$1,419,8600 total
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-1325,0000 total
    Common Stock (25,000 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-1312,0000 total
    Common Stock (12,000 underlying)
  • Award

    Common Stock

    2017-10-13+75,000127,000 total
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$2.06/sh84,000$173,0400 total
    Exercise: $9.12Exp: 2026-03-15Common Stock (84,000 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$1.53/sh84,000$128,5200 total
    Exercise: $9.65Exp: 2027-03-08Common Stock (84,000 underlying)
  • Exercise/Conversion

    Common Stock

    2017-10-13+52,00052,000 total
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-136,0000 total
    Common Stock (6,000 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-139,0000 total
    Common Stock (9,000 underlying)
Footnotes (10)
  • [F1]Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
  • [F10]Under its terms the option became exercisable in installments with 25% vesting on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
  • [F2]Shares of SCLN common stock received in settlement of performance rights not constituting derivative securities.
  • [F3]Granted under Issuer's 2005 Equity Incentive Plan.
  • [F4]Under its terms the option became exercisable in installments with 25% vesting on March 14, 2015 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger").
  • [F5]The option was canceled immediately prior to the Merger in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
  • [F6]Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
  • [F7]Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
  • [F8]Granted under Issuer's 2015 Equity Incentive Plan.
  • [F9]Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.

Issuer

SCICLONE PHARMACEUTICALS INC

CIK 0000880771

Entity typeother

Related Parties

1
  • filerCIK 0001576318

Filing Metadata

Form type
4
Filed
Oct 15, 8:00 PM ET
Accepted
Oct 16, 5:14 PM ET
Size
27.5 KB